Takeda launches Latuda (lurasidone) in Switzerland

Takeda announced the launch of Latuda (lurasidone), its atypical antipsychotic for the treatment of patients with schizophrenia. The launch of lurasidone in Switzerland marks the beginning of the drug's European launch.

In clinical trials lurasidone has been shown to demonstrate effective symptom control as early as day four of treatment. In addition, it has been shown to have a favourable side effect profile and help patients maintain their cardiometabolic health, improving the long-term patient outcomes¹.

References

1. Daumit GL et al. Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 2008 105(1–3):175-187.